This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Value Stocks to Invest in for the Second-Half 2025 Market Shift
by Sumit Singh
Hudbay, StoneCo, Centene, and CVS stand out as top value picks for H2 2025 with strong cash flow and growth prospects.
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, ODP, STNE and PSFE are some such stocks.
Are You Looking for a Top Momentum Pick? Why StoneCo Ltd. (STNE) is a Great Choice
by Zacks Equity Research
Does StoneCo Ltd. (STNE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Look Bullish on StoneCo (STNE): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), StoneCo (STNE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
StoneCo Stock Rides on Product Innovation, Attractive Valuation
by Sridatri Sarkar
STNE surges ahead with a full-stack platform and bold product innovation aimed at Brazil's booming digital payment market.
STNE vs. PYPL: Why StoneCo Offers More Upside Than PayPal Currently
by Urmimala Biswas
STNE is outpacing PYPL with strong buybacks, local innovation and greater valuation upside potential.
STNE vs. FFIV: Which Stock Is the Better Value Option?
by Zacks Equity Research
STNE vs. FFIV: Which Stock Is the Better Value Option?
Zacks.com featured highlights include StoneCo, Cullen/Frost Bankers, Intuit and The Mosaic
by Zacks Equity Research
STNE, CFR, INTU, and MOS show resilient sales growth potential, offering stability amid market uncertainty in 2025.
4 Stocks With Robust Sales Growth to Buy Despite Market Uncertainty
by Swayta Shah
INTU, STNE, CFR and MOS show strong sales growth and healthy cash flow, some of the key traits for navigating market uncertainty.
5 Low Price-to-Book Value Stocks That You Can Buy in June
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
StoneCo Eyes 18% EPS Growth in 2025: What's Fueling It?
by Sridatri Sarkar
STNE targets 14% gross profit growth, along with 18% EPS growth in 2025, backed by repricing gains, cash sweep moves and credit portfolio expansion.
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
by Sumit Singh
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Buy 5 Mid-Cap Fintech Stocks for a Stronger Long-Term Portfolio
by Nalak Das
Mid-cap fintech stocks like BILL, FOUR, OPFI, ACIW and STNE are riding on strong growth trends, offering long-term portfolio upside.
Is MercadoLibre's Fintech User Base Set to Keep Climbing in 2025?
by Zacks Equity Research
MELI's fintech user base is set to keep climbing, fueled by deeper engagement and wider adoption of digital financial services.
STNE Stock Rides on Deposit Strategies, Attractive Valuation
by Sridatri Sarkar
StoneCo's Q1 deposit surges 38% as Pix adoption, bundling and a new cash sweep strategy reshape its funding model.
StoneCo's Q1 Repricing Drives Gross Profit Surge Amid Rate Pressures
by Sridatri Sarkar
STNE's broad Q1 repricing initiative raises gross profit by 19% and EPS by 36%, outpacing guidance despite rate headwinds.
HPE Stock Rises 5% as Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Hewlett Packard Enterprise jumps 4.6% after Q2 results top estimates, with AI and hybrid cloud fueling 6% revenue growth despite margin pressure.
CrowdStrike Beats on Q1 Earnings, Stock Down on Revenue Miss
by Zacks Equity Research
CRWD surpasses Q1 earnings estimates, but a slight revenue miss and margin pressures sent the stock down 6.5% after hours.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
Fintech Tailwind and Cheap Valuation Make StoneCo a Buy Today
by Urmimala Biswas
STNE gains from fintech tailwinds, repricing power and PIX monetization while trading below peers on valuation.
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
by Sumit Singh
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Science Applications Stock Plunges 13% as Q1 Earnings Miss Estimates
by Zacks Equity Research
SAIC stock declines 13% after Q1 earnings miss, flat profits and margin pressure weigh despite modest revenue growth.
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus
by Santanu Roy
StoneCo, Axon and Intuit stand out as Zacks-backed winners amid market weakness and rising global trade tensions.
STNE or INFA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
STNE vs. INFA: Which Stock Is the Better Value Option?
AFRM Extends Partnership With Williams-Sonoma to Bring BNPL to Canada
by Zacks Equity Research
Affirm expands BNPL services to Canada through Williams-Sonoma, boosting its reach across premium brands like West Elm and Pottery Barn.